
Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status
Ribociclib (Kisqali) combined with a nonsteroidal aromatase inhibitor (NSAI) demonstrated consistent benefits in invasive disease-free survival (iDFS), distant disease-free survival (DDFS), recurrence-free survival (RFS), and distant relapse-free survival …